Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jul 2023 Results assessing the safety and tolerability of single dose of one-month donepezil IM depot (GB-5001) in healthy male volunteers and comparing pharmacokinetic parameters of 70mg donepezil IM depot and 10mg once daily oral tablet (Aricept) in human, presented at the Alzheimer's Association International Conference 2023.
06 Jul 2023 Status changed from recruiting to completed.
09 Nov 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com